VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RAPP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RAPPRapport Therapeutics, Inc. Common Stock
$23.40$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksRAPPCash Flow

Rapport Therapeutics, Inc. Common Stock (RAPP) Cash Flow Statement

4Y historyFree accessUpdated daily

Operating cash outflow of $41.6M in 2026Q3 tracked 103% of the $40.2M net loss, and free cash flow burn more than doubled from roughly -$17M per quarter in 2024, suggesting liquidity is tightening quickly against the $74.8M cash position.

Income StatementBalance SheetCash FlowRatios

RAPP Cash Flow Statement

Annual statement

RAPP Cash Flow Statement

Rapport Therapeutics, Inc. Common Stock (RAPP) cash flow statement — 4-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22
Cash from Operations-120.85M-87.47M-64.83M-27.18M-3.24M
Operating CF Margin %-----
Operating CF Growth %-239.27%-34.93%-138.5%-738.4%-
Net Income-150.47M-111.48M-78.31M-34.79M-10.65M
Depreciation & Amortization902K1.02M839K112K15K
Stock-Based Compensation27.49M18.86M10.23M3.52M609.82K
Deferred Taxes00000
Other Non-Cash Items-616K636K4.82M1.32M5.3M
Working Capital Changes1.84M3.5M-2.42M2.65M1.49M
Change in Receivables-171K0000
Change in Inventory00000
Change in Payables-1.28M2.21M-346K856K0
Cash from Investing-59.72M-187.47M-170.14M-78.86M-5.28M
Capital Expenditures-333K-616K-2.4M-1.64M-284K
CapEx % of Revenue1.67%----
Acquisitions00000
Investments-----
Other Investing401K03.21M0-5M
Cash from Financing3.96M270.79M221.63M145.14M39.69M
Debt Issued (Net)00007.9M
Equity Issued (Net)4.42M270.79M221.62M145.27M31.79M
Dividends Paid00000
Share Repurchases-5K-1K0-4K0
Other Financing-453K07K-134K0
Net Change in Cash-176.6M-4.16M-13.34M39.09M31.16M
Free Cash Flow-121.18M-88.09M-67.23M-28.82M-3.53M
FCF Margin %-605.91%----
FCF Growth %-55.58%-31.02%-133.31%-717.27%-
FCF per Share-2.54-2.26-3.24-19.14-0.18
FCF Conversion (FCF/Net Income)0.81x0.78x0.83x0.78x0.30x
Interest Paid00000
Taxes Paid00000

Key Metrics

Growth RegimeExpanding
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Equity dilution funding dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Burn Tracks Net Losses Closely

According to reported quarterly figures, RAPP's operating cash flow has consistently run at 65% to 103% of its net loss across the ten quarters, with 2026Q3 showing operating outflows of $41.6M against a $40.2M net loss.

The conversion ratio sits near 1.0 in several recent quarters, which suggests reported losses are almost entirely cash-consuming rather than masked by large non-cash charges. Stock-based compensation of $7.6M in 2026Q3 explains only a modest portion of the gap, so the bulk of the loss reflects real clinical spending. This pattern indicates earnings quality is not the primary concern; the question is the pace of cash consumption relative to available funding.

Free Cash Flow Deficit Widening Into Pivotal Stage

Based on reported figures, RAPP's free cash flow turned from roughly -$17M per quarter in 2024 to -$41.6M in 2026Q3, more than doubling the burn rate as pivotal-stage activity ramped.

Because the company has no revenue base, free cash flow margin is not meaningful and the trajectory is best read in absolute dollars. The sequential acceleration in outflows through 2026 is consistent with RAP-219 pivotal trial costs entering full execution. Investors should monitor whether the burn rate stabilizes or continues to rise, as this directly determines the timing of any further capital raise.

Negligible Capital Intensity Confirms Outsourced Model

As reported in the cash flow statements, RAPP's capital expenditures remained below $0.3M in most quarters, representing near-zero capital intensity against quarterly operating outflows exceeding $40M.

Minimal capex, with D&A of roughly $0.2M per quarter, indicates the company relies on contract research organizations rather than owned laboratory or manufacturing infrastructure. This asset-light structure means cash consumption is driven by variable clinical spend rather than fixed plant commitments. The low capital base offers flexibility to scale trials up or down, though it also leaves the company dependent on external partners for execution timing.

Working Capital Swings Add Quarterly Volatility

Per the reported cash flow data, working capital changes ranged from a $9.5M inflow to a $9.5M outflow across recent quarters, adding noticeable noise to operating cash flow beyond the underlying loss trend.

The lumpy movements, including a $9.5M outflow in 2026Q3 and an $8.5M inflow in 2026Q2, likely reflect the timing of accrued clinical invoices and payables to trial sites. Such swings can make a single quarter's operating cash flow a poor proxy for run rate. Analysts should model burn on a trailing basis to avoid over- or under-stating the underlying consumption pace.

Reported Cash Balance May Overstate Runway

Based on reported figures, the $52.6M cash position appears small relative to the most recent quarterly operating outflow of $41.6M, implying limited coverage of roughly one to two quarters at current burn.

Taken at face value, the cash balance covers only about one quarter of the latest operating burn, which suggests the company is likely to require additional financing in the near term. The reported figure may not capture all liquidity following the 2024 IPO, so the runway conclusion warrants verification against the latest balance sheet. Investors should monitor financing announcements, as dilution appears to be a plausible path to fund pivotal trials.

RAPP — Frequently Asked Questions

Quick answers to the most common questions about buying RAPP stock.

How much cash does Rapport Therapeutics, Inc. Common Stock (RAPP) generate from operations?

Rapport Therapeutics, Inc. Common Stock (RAPP) generated $-87.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Rapport Therapeutics, Inc. Common Stock's free cash flow?

Rapport Therapeutics, Inc. Common Stock (RAPP) reported negative free cash flow of $88.1M in 2025, indicating capital requirements exceeded cash from operations.

What is Rapport Therapeutics, Inc. Common Stock's capital expenditure (CapEx)?

Rapport Therapeutics, Inc. Common Stock (RAPP) spent $0.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Rapport Therapeutics, Inc. Common Stock distribute cash to shareholders?

In 2025, Rapport Therapeutics, Inc. Common Stock (RAPP) spent $0.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.